NNovo Nordisk Read More Novo Nordisk Faces Generic Onslaught and Dividend Adjustment in Key Market2026-03-30 Novo Nordisk’s semaglutide patent expires in India, sparking generic price war. Stock hits 52-week low while trading ex-dividend,…